VYNE News & Events

VYNE Therapeutics and Yarrow Bioscience entered into a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the Merger, the combined company expects to operate as Yarrow Bioscience, Inc. and trade on Nasdaq under the ticker symbol "YARW". Following completion of the Merger, the combined company plans to focus on advancing YB-101, a clinical-stage, potentially first-in-class TSHR antibody for the treatment of GD and TED. In support of the Merger, a syndicate of healthcare investors led by RTW Investments, with participation from OrbiMed, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners and Perceptive Advisors, has committed to pre-closing financings in Yarrow totaling approximately $200M in cash proceeds. The combined company's cash balance at closing is expected to fund operations into 2028, including the advancement of the combined company's lead program YB-101, into a Phase 1b/2b trial in patients with GD, which is expected to be conducted in the United States and other territories. Phase 1b data is expected in the second half of 2027. In parallel, a Phase 1 trial, which is being conducted by licensing partner GenSci, is evaluating the safety and efficacy of YB-101 in patients with TED in China. Prior to closing, VYNE expects to declare a cash dividend to pre-Merger VYNE stockholders to distribute excess net cash, which is expected to be approximately $14.5M to $16.5M. Under the terms of the merger agreement, the pre-Merger VYNE stockholders are expected to own approximately 3% of the combined company, and the pre-Merger Yarrow stockholders are expected to own approximately 97% of the combined company, which is subject to adjustment in accordance with the definitive merger agreement. The Merger has received unanimous approval by the boards of directors of both companies and is expected to close in the second quarter of 2026, subject to certain closing conditions, including, among other things, approval by the stockholders of each company, the effectiveness of a registration statement on Form S-4 to be filed with the U.S. Securities and Exchange Commission to register the securities to be issued in connection with the Merger and the satisfaction of other customary closing conditions. The combined company will be named "Yarrow Bioscience, Inc." and be led by Rebecca Frey, Yarrow's CEO and a member of Yarrow's board of directors. In addition, Lori Payton, Ph.D. is joining Yarrow's management team as Chief Development Officer.

Reports Q3 revenue $169k vs $121k last year. "Consistent with our focus on growing shareholder value, we have made considerable progress in evaluating a number of potential value-creating opportunities as part of our strategic review process, and we look forward to providing an update on these efforts as soon as possible," said David Domzalski, President and Chief Executive Officer of VYNE. "In parallel, we initiated a repeat 12-week, non-clinical toxicology study in dogs for VYN202. We believe a successful outcome from this study will enable us to remove the partial hold for testing VYN202 in male clinical subjects across a range of potential immuno-inflammatory diseases."

Reports Q2 revenue $69,000 vs $198,000 last year. "The strength of our recent clinical and preclinical findings for VYN202 provides a compelling scientific foundation as we determine the best path forward for the VYN202 program," said David Domazalski, President and Chief Executive Officer of VYNE. "In conjunction, we have implemented cost reductions that are expected to extend our cash runway into the first half of 2027, giving us additional flexibility during this period."